OncoMatch/Clinical Trials/NCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Is NCT04496349 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including APG-115 and APG-2575 for t-prolymphocytic leukemia.
Treatment: APG-115 · APG-2575 — The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any prior therapy
relapsed/refractory T-PLL who have active disease and have received at least one prior therapy
Cannot have received: MDM2 inhibitor
Patient previously treated with a murine double minute 2 (MDM2) inhibitor
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 500/mm˄3; hemoglobin ≥ 60 g/L; platelet count ≥ 30,000/mm˄3
Kidney function
adequate organ function
Liver function
adequate organ function
Absolute neutrophil count (ANC) ≥ 500/mm˄3; hemoglobin ≥ 60 g/L; platelet count ≥ 30,000/mm˄3; Patients with adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04496349 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MDM2 inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages